You are not telling us anything new. You had SAVR, yes SAVR does last a lot longer than the current TAVR which is why for younger patient , it is currently preferred over TAVR.
But AVR is the game changer here. It may well last as long as SAVR for a fraction of the risk of an open heart.
You are quite muddled up. SAVR and TAVR are different beasts. We are talking about dominating the TAVR space currently though the initial now halted SAVR studies in Belgium also holds a lot of promise on the SVAR space .
As Pikey said, a neighbour being a QC does not make one a lawyer. It does not happen by osmosis or nearology.
Anteris Channel 9 Interview 2022, page-35
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.71 |
Change
0.010(0.06%) |
Mkt cap ! $301.9M | |||
| Open | High | Low | Value | Volume |
| $16.00 | $16.01 | $15.49 | $3.254M | 230.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $15.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 700 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |